Statins and blockers of the renin-angiotensin system: Vascular protection beyond their primary mode of action

Hypertension

Volumn 34, Issue 4 II, 1999, Pages 987-996

  Faggiotto, Agostino ^b   Paoletti, Rodolfo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b NONE

Author keywords

Angiotensin converting enzyme inhibitors; Atherosclerosis; Coronary disease; Pleiotropy; Receptors, angiotensin II; Renin angiotensin system; Statins

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; BRADYKININ; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; TASOSARTAN;

ANTIOXIDANT ACTIVITY; ARTERY WALL; ATHEROGENESIS; CARDIOVASCULAR SYSTEM; CELL PROLIFERATION; CONFERENCE PAPER; DRUG ACTIVITY; DRUG EFFECT; ENDOTHELIUM; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; PRIORITY JOURNAL; PROTECTION; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; THROMBOCYTE FUNCTION; ANIMAL; CARDIOVASCULAR DISEASE; METABOLISM; PATHOPHYSIOLOGY; REVIEW;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RENIN-ANGIOTENSIN SYSTEM;

EID: 0033210904     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.hyp.34.4.987     Document Type: Conference Paper

References (101)

1. Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA. 1986;256:2835-2838.
2. Castelli WP, Anderson K. A population at risk: prevalence of high cholesterol levels in hypertensive patients of the Framingham Study. Am J Med. 1986;80(suppl 2A):23-32.
3. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-1307.
4. Scandinavian Simvastatin Survival Group. Randomized trial of cholesterol lowering in 4444 patients with coronary disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
5. Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation. 1998;97:1411-1420.
6. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun C, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335: 1001-1009.
7. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279: 1615-1622.
8. Gould KL, Martucci JP, Goldberg DI, Hess MJ, Edens RP. Latifi R, Dudrick SJ. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease: a potential noninvasive marker of healing coronary endothelium. Circulation. 1994;89: 1530-1538.
9. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results, 1: reduction in incidence of coronary heart disease. JAMA. 1984;251:351-364.
10. Buchwald H, Campos CT, Boen JR. Disease-free intervals after partial ileal bypass in patients with coronary heart disease and hypercholesterolemia: report from the Program on the Surgical Control of the Hyperlipidemias (POSCH). J Am Coll Cardiol. 1995;26:351-357.
11. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998;97:1129-1135.
12. Brandes RP, Behra A, Lebherz C, Boger RH, Bode-Boger SM, Mugge A. Lovastatin maintains nitric oxide-but not EDHF-mediated endothelium-dependent relaxation in the hypercholesterolemic rabbit carotid artery. Atherosclerosis. 1999;142:97-104.
13. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, Liao JK. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A. 1998;95:8880-8885.
14. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C, Lamas S. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest. 1998;101:2711-2719.
15. Jin ZQ, Chen X, Ramipril-induced delayed myocardial protection against free radical injury involves bradykinin B2 receptor-NO pathway and protein synthesis. Br J Pharmacol. 1998;125:556-562.
16. Matoba S, Tatsumi T, Keira N, Kawahara A, Akashi K, Kobara M, Asayama J, Nakagawa M. Cardioprotective effect of angiotensin-converting enzyme inhibition against hypoxia/reoxygenation injury in cultured rat cardiac myocytes. Circulation. 1999;99:817-822.
17. Vanhoutte PM. Endothelial dysfunction and inhibition of converting enzyme. Eur Heart J. 1998;19(suppl):J7-J15.
18. Resende AC, Ballejo G, Salgado MC. Role of non-nitric oxide, non-prostaglandin endothelium-derived relaxing factor(s) in bradykinin vasodilation. Braz J Med Biol Res. 1998;31:1229-1235.
19. Essig M, Nguyen G, Prie D, Escoubet B, Sraer JD, Friedlander G. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells: role of geranylgeranylation and Rho proteins. Circ Res. 1998:83:683-690.
20. Bellosta S, Bernini F, Ferri N, Quarato P, Canavesi M, Arnaboldi L, Fumagalli R, Paoletti R, Corsini A. Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis. 1998;137:S101-S109.
21. Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II: evidence of a potential interaction between the reninangiotensin system and fibrinolytic function. Circulation. 1993;87: 1969-1973.
22. Colli S, Eligini S, Lalli M, Camera M, Paoletti R, Tremoli E. Vastatins inhibit tissue factor in cultured human macrophages: a novel mechanism of protection against atherothrombosis. Arterioscler Thromb Vasc Biol. 1997;17:265-272.
23. Dietz R, von Harsdorf R, Gross M, Kramer J, Gulba D, Willenbrock R, Osterziel KJ. Angiotensin II and coronary artery disease, congestive heart failure, and sudden cardiac death. Basic Res Cardiol. 1998;93(S2): 101-108.
24. Tayeh MA, Scicli AG. Angiotensin II and bradykinin regulate the expression of P-selectin on the surface of endothelial cells in culture. Proc Assoc Am Phys. 1998;110:412-421.
25. Corsini A, Bernini F, Quarato P, Donetti E, Bellosta S, Fumagalli R, Paoletti R, Soma VM. Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Cardiology. 1996;87: 458-468.
26. Mancini GB. Role of angiotensin-converting enzyme inhibition in reversal of endothelial dysfunction in coronary artery disease. Am J Med. 1998;105:40S-47S.
27. Vrtovsnik F, Couette S, Prie D, Lallemand D, Friedlander G. Lovastatin-induced inhibition of renal epithelial tubular cell proliferation involves a p21ras activated, AP-1-dependent pathway. Kidney Int. 1997; 52:1016-1027.
28. Ferrari R, Ceconi C, Curello S, Pepi P, Mazzoletti A, Visioli O. Cardioprotective effect of angiotensin converting enzyme inhibitors in patients with coronary artery disease. Cardiovasc Drugs Ther. 1996;10: 639-647.
29. Aviram M, Hussein O, Rosenblat M, Schlezinger S, Hayek T, Keidar S. Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy. J Cardiovasc Pharmacol. 1998;31:39-45.
30. Guijarro C, Blanco-Colio LM, Ortego M, Alonso C, Ortiz A, Plaza JJ, Diaz C, Hernandez G, Edigo J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res. 1998;83:490-500.
31. Tan A, Levrey H, Dahm C, Polunovsky VA, Rubins J, Bitterman PB. Lovastatin induces fibroblast apoptosis in vitro and in vivo: a possible therapy for fibroproliferative disorders. Am J Respir Crit Care Med. 1999;159:220-227.
32. Holtz J. Role of ACE inhibition or AT1 blockade in the remodeling following myocardial infarction. Basic Res Cardiol. 1998;93(S2): 92-100.
33. Nakagawa H, Mutoh T, Kumano T, Kuriyama M. HMG-CoA reductase inhibitor-induced L6 myoblast cell death: involvement of the phosphatidylinositol 3-kinase pathway. FEBS Lett. 1998;438:289-292.
34. Jiang J, Roman RJ. Lovastatin prevents development of hypertension in spontaneously hypertensive rats. Hypertension. 1997;30:968-974.
35. Mitani H, Bandoh T, Ishikawa J, Kimura M, Totsuka T, Hayashi S. Inhibitory effects of fluvastatin, a new HMG-CoA reductase inhibitor, on the increase in vascular ACE activity in cholesterol-fed rabbits. Br J Pharmacol. 1996;119:1269-1275.
36. Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation. 1998;97:1411-1420.
37. Rudich SM, Mongini PK, Perez RV, Katznelson S. HMG-CoA reductase inhibitors pravastatin and simvastatin inhibit human B-lymphocyte activation. Transplant Proc. 1998;30:992-995.
38. Muldoon MF, Flory JD, Marsland A, Manuck SB, Whiteside TL, Rabin B. Effects of lovastatin on the immune system. Am J Cardiol. 1997;80: 1391-1394.
39. Katznelson S, Wang XM, Chia D, Ozawa M, Zhong HP, Hirata M, Terasaki PI, Kobashigawa JA. The inhibitory effects of pravastatin on natural killer cell activity in vivo and on cytotoxic T lymphocyte activity in vitro. J Heart Lung Transplant. 1998;17:335-340.
40. Park YS, Guijarro C, Kim Y, Massy ZA, Kasiske BL, Keane WF, O'Donnell MP. Lovastatin reduces glomerular macrophage influx and expression of monocyte chemoattractant protein-1 mRNA in nephrotic rats. Am J Kidney Dis. 1998;31:190-194.
41. Kreuzer J, Bader J, Jahn L, Hautmann M, Kubler W, Von Hodenberg E. Chemotaxis of the monocyte cell line U937: dependence on cholesterol and early mevalonate pathway products. Atherosclerosis. 1991;90: 203-209.
42. Bellosta S, Via D, Canavesi M, Pfister P, Fumagalli R, Paoletti R, Bernini F. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol. 1998;18:1671-1678.
43. Kitahara M, Kanaki T, Toyoda K, Miyakoshi C, Tanaka S, Tamaki T, Saito Y. NK-104, a newly developed HMG-CoA reductase inhibitor, suppresses neointimal thickening by inhibiting smooth muscle cell growth and fibronectin production in balloon-injured rabbit carotid artery. J Pharmacol. 1998;77:117-128.
44. Giroux LM, Davignon J, Naruszewicz M. Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages. Biochim Biophys Acta. 1993;1165:335-358.
45. Zambrana JL, Lopez-Miranda J, Blanco A, Arizon JM, Jansen S, Paniagua JA, Jimenez-Pereperez JA, Concha M, Perez-Jimenez F. Bezafibrate and lovaslatin decrease the oxidizability of low-density lipoproteins in heart transplant recipients with hyperlipidemia. J Heart Lung Transplant. 1998;17:1213-1219.
46. Singh RB, Singh NK, Rastogi SS, Wander GS, Aslam M, Onouchi Z, Kummerow FA, Nangia S. Antioxidant effects of lovastatin and vitamin E on experimental atherosclerosis in rabbits. Cardiovasc Drugs Ther. 1997;11:575-580.
47. Jin ZQ, Chen X. Bradykinin mediates myocardial ischaemic preconditioning against free radical injury in guinea-pig isolated heart. Clin Exp Pharmacol Physiol. 1998;25:932-935.
48. Kohno M, Murakawa K, Yasunari K, Yokokawa K, Horio T, Kano H, Minami M, Yoshikawa J. Improvement of erythrocyte deformability by cholesterol-lowering therapy with pravastatin in hypercholesterolemic patients. Metabolism. 1997;46:287-291.
49. Tsuda Y, Satoh K, Kitadai M, Takahashi T, Izumi Y, Hosomi N. Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia. Atherosclerosis. 1996; 122:225-233.
50. Farnier M, Davignon J. Current and future treatment of hyperlipidemia: the role of statins. Am J Cardiol. 1998;82:J3-J10.
51. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts. Lancet. 1995;346:1647-1653.
52. MacMahon S, Sharpe N, Gamble G, Hart H, Scott J, Simes J, White H. Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID. Circulation. 1997;97:1784-1790.
53. Corsini A, Pazzucconi F, Pfister P, Paoletti R, Sirtori CR. Inhibitor of proliferation of arterial smooth-muscle cells by fluvastatin. Lancet. 1996;348:1584.
54. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, Chia D, Terasaki PI, Sabad A, Cogert GA, Trosian K, Hamilton MA, Moriguchi JD, Kawata N, Hage A, Drinkwater DC, Stevenson LW. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 1995;333:621-627.
55. Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RG, Rodan GA, Reszka AA. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci U S A. 1999;96:133-138.
56. Cui Q, Wang GJ, Su CC, Balian G. The Otto Aufranc Award: lovastatin prevents steroid induced adipogenesis and osteonecrosis. Clin Orthop Rel Res. 1997;344:8-19.
57. Soma MR, Baetta R, De Renzis MR, Mazzini G, Davegna C, Magrassi L, Butti G, Pezzotta S, Paoletti R, Fumagalli R. In vivo enhanced antitumor activity of carmustine [N,N′-bis(2-chloroethyl)-N-nitrosourea] by simvastatin. Cancer Res. 1995;55:597-602.
58. Melichar B, Ferrandina G, Verschraegen CF, Loercher A, Abbruzzese JL, Freedman RS. Growth inhibitory effects of aromatic fatty acids on ovarian tumor cell lines. Clin Cancer Res. 1998;4:3069-3076.
59. Dimitroulakos J, Nohynek D, Backway KL, Hedley DW, Yeger H, Freedman MH, Minden MD, Penn LZ. Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: a potential therapeutic approach. Blood. 1999;93:1308-1318.
60. Rubins JB, Greatens T, Kratzke RA, Tan AT, Polunovsky VA, Bitterman P. Lovastatin induces apoptosis in malignant mesothelioma cells. Am J Respir Crit Care Med. 1998;157:1616-1622.
61. Thibault A, Samid D, Tompkins AC, Figg WD, Cooper MR, Hohl RJ, Trepel J, Liang B, Patronas N, Venzon DJ, Reed E, Myers CE. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res. 1996;2:483-491.
62. Larner J, Jane J, Laws E, Packer R, Myers C, Shaffrey M. A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme. Am J Clin Oncol. 1998;21:579-583.
63. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative Northe Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1435.
64. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
65. Cohn JN, Johnson G, Zieshe J, Frederick C, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, Bhat G, Goldman S, Fletcher RD, Doherty J, Hughes CV, Carson P, Cintron G, Shabetai R, Haakenson C. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303-310.
66. AIRE Study Group. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821-828.
67. Kober L, Torp-Pederson C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC, Aliuot E, Persson S, Camm AJ, for the Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1995;333:1670-1676.
68. Pfeffer MA, Braunwald EA, Moye LA, Basta L, Brown EJJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1992;327:669-677.
69. Yusuf S, Pepine CJ, Garces C, Pouleur H, Salem D, Kostis J, Benedict C, Rousseau M, Bourassa M, Pitt B. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet. 1992;340:1173-1178.
70. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction: results of the Cooperative North Scandinavian Enalapril Study II (CONSENSUS II). N Engl J Med. 1992; 327:678-684.
71. Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med. 1995;332:80-85.
72. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly or together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet. 1994:343:1115-1122.
73. Pfeffer JM, Fischer TA, Pfeffer MA. Angiotensin-converting enzyme inhibition and ventricular remodeling after myocardial infarction. Annu Rev Physiol. 1995;57:805-826.
74. Skidgel RA, Erdos E. Biochemistry of angiotensin I-converting enzyme. In: Robertson JIS, Nicholls MG, eds. The Renin-Angiotensin System. New York, NY: Raven Press Ltd; 1993:10.1-10.10.
75. Sawyer JW, Timmis AD. Angiotensin-converting enzyme inhibitors and coronary heart disease. Cardiovasc Drugs Ther. 1996:10:631-637.
76. Lonn EM, Yusuf S, Jha P. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation. 1994; 90:2056-2068.
77. Horiuchi M, Akisnita M, Dzau VJ. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension. 1999;33:613-621.
78. Du Y, Qiu J, Nelson SH, Wang DH. Regulation of type 1 Ang II receptor in vascular tissue: role of α1-adrenoreceptor. Am J Physiol. 1997;273:R1224-R1229.
79. Ardaillou R. Angiotensin II receptors. J Am Soc Nephrol. 1999;11: S30-S39.
80. Inagami T, Eguchi S, Numaguchi K, Motley ED, Tang H, Matsumoto T, Yamakawa T. Cross-talk between angiotensin II receptors and the tyrosine kinases and phosphatases. J Am Soc Nephrol. 1999:10(suppl 11):S57-S61.
81. Allen AM, Zhuo J, Mendelsohn FA. Localization of angiotensin AT1 and AT2 receptors. J Am Soc Nephrol. 1999;10(S11):23-29.
82. Csajka C, Buclin T, Brunner HR, Biollaz J. Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists. Clin Pharmacol. 1997;32:1-29.
83. Inada Y, Murakami M, Kaido K, Nakao K. Effects of the new angiotensin II type 1 receptor antagonist KRH-594 on several types of experimental hypertension. Arzneimittelforschung. 1999;49:13-21.
84. Anderson IK, Drew GM. The antihypertensive profile of the angiotensin AT1 receptor antagonist. GR138950, and the influence of potential homeostatic compensatory mechanisms in renal hypertensive rats. Br J Pharmacol. 1998;125:1236-1246.
85. Morgan TO, Delbridge LM. Angiotensin blocking drugs and the heart beyond 2000. J Am Soc Nephrol. 1999;10(S11):243-247.
86. Jalowy A, Schulz R, Heusch G. AT1 receptor blockade in experimental myocardial ischemia/reperfusion. J Am Soc Nephrol. 1999;10:S11: 129-136.
87. Unger T, Culman J, Gohlke P. Angiotensin II receptor blockade and end-organ protection: pharmacological rationale and evidence. J Hypertens. 1998;16:S3-S9.
88. Nickenig G, Roling J, Strehlow K, Schnabel P, Bohm M. Insulin induces upregulation of vascular AT1 receptor gene expression by posttranscriptional mechanisms. Circulation. 1998;98:2453-2460.
89. Bennai F, Morsing P, Paliege A, Ketteler M, Mayer B, Tapp R, Bachmann S. Normalizing the expression of nitric oxide synthase by low-dose AT1 receptor antagonism parallels improved vascular morphology in hypertensive rats. J Am Soc Nephrol. 1999;10(S11):104-115.
90. Yanagitani Y, Rakugi H, Okamura A, Moriguchi K, Takiuchi S, Ohishi M, Suzuki K, Higaki J, Ogihara T. Angiotensin II type 1 receptor-mediated peroxide production in human macrophages. Hypertension. 1999;33:335-339.
91. Nishimura Y, Xu T, Johren O, Hauser W, Saavedra JM. The angiotensin ATI receptor antagonist CV-11974 regulates cerebral blood flow and brain angiotensin AT1 receptor expression. Basic Res Cardiol. 1998; 93(S2):63-68.
92. $Raghavendra V, Chopra K, Kulkami SK. Involvement of cholinergic system in losartan-induced facilitation of spatial and short-term working memory. Neuropeptides. 1998;32:417-421.
93. Tschudi MR, Noll G, Luscher TP. Pharmacotherapy of arteriosclerosis and its complications: effect of ACE inhibitors and HMG-CoA-reductase inhibitors. Schweiz Med Wochenschr. 1997;127:636-649.
94. Pitt B. The potential use of angiotensin-converting enzyme inhibitors in patients with hyperlipidemia. Am J Cardiol. 1997;79:24-28.
95. Mitani H, Bandoh T, Ishikawa J, Kimura M, Totsuka T, Hayashi S. Inhibitory effects of fluvastatin, a new HMG-CoA reductase inhibitor, on the increase in vascular ACE activity in cholesterol-fed rabbits. Br J Pharmacol. 1996;119:1269-1275.
96. Waeber B, Greminger P, Riesen W, Darioli R, Simeon-Dubach D, Wunderlin R. Combined treatment with captopril, hydrochlorothiazide and pravastatin in dyslipidemic hypertensive patients. Blood Press. 1995;4:358-362.
97. Nazzaro P, Manzari M, Merlo M, Triggiani R, Scarano A, Ciancio L, Pirrelli A. Distinct and combined vascular effects of ACE blockade and HMG-CoA reductase inhibition in hypertensive subjects. Hypertension. 1999;33:719-725.
98. Farnier M, Davignon J. Current and future treatment of hyperlipidemia: the role of statins. Am J Cardiol. 1998;82:3J-10J.
99. Adams KF Jr. Angiotensin-conserting enzyme inhibition and vascular remodeling in coronary artery disease. Coron Artery Dis. 1998;9:675-684.
100. Cashin-Hemphill L, Holmvang G, Chan RC, Pitt B, Dinsmore RE, Lees RS. Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: no answer yet: QUIET Investigators: QUinapril Ischemic Event Trial. Am J Cardiol. 1999;83:43-47.
101. Mancini GB. Role of angiotensin-converting enzyme inhibition in reversal of endothelial dysfunction in coronary artery disease. Am J Med. 1998;105:S40-SS47.